Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:12 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1033–1056 of 1,097 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Vehicle Control Clear all
Completed Phase 3 Interventional Results available

A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris

NCT02886715
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene Cream 0.1%, Tazorac®, Placebo
Drug
Lead sponsor
Fougera Pharmaceuticals Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
1,110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
25
States / cities
Tucson, Arizona • Conway, Arkansas • Hot Springs, Arkansas + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2018 · Synced Oct 22, 2026, 5:12 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

NCT05147233
View directory record Official record
Conditions
Inflammation Eye Pain, Postoperative Cataract
Interventions
OCS-01, Vehicle
Drug
Lead sponsor
Oculis
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
25
States / cities
Chandler, Arizona • Phoenix, Arizona • Fayetteville, Arkansas + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2025 · Synced Oct 22, 2026, 5:12 AM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy Study of DSP-Visulex for the Treatment of Anterior Uveitis

NCT02309385
View directory record Official record
Conditions
Non-Infectious Anterior Uveitis
Interventions
8% Dexamethasone Sodium Phosphate - Visulex, 15% Dexamethasone Sodium Phosphate - Visulex, Prednisolone Acetate (1%) Eye Drops
Drug
Lead sponsor
Aciont Inc
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Cambridge, Massachusetts • Charlotte, North Carolina • Fargo, North Dakota + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Oct 22, 2026, 5:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of a Topical Treatment for Dry Age Related Macular Degeneration

NCT01922128
View directory record Official record
Conditions
Nonexudative Age-related Macular Degeneration
Interventions
MC-1101, Placebo
Drug
Lead sponsor
MacuCLEAR, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Artesia, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 22, 2026, 5:12 AM EDT
Completed Phase 3 Interventional

A Multi-centre, Double-blind, Randomized, Vehicle-controlled Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)

NCT02859519
View directory record Official record
Conditions
Distal Subungual Onychomycosis
Interventions
MOB015B, MOB015B Vehicle
Drug
Lead sponsor
Moberg Pharma AB
Industry
Eligibility
12 Years to 75 Years
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
9
States / cities
Multiple Locations, California • Multiple Locations, Florida • Multiple Locations, Idaho + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2020 · Synced Oct 22, 2026, 5:12 AM EDT
Recruiting Phase 3 Interventional

Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp

NCT07144345
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20%, Vehicle containing excipients only (VEH) without active ingredient, Blue Light Photodynamic Therapy Illuminator device, BLU-U® model 4170E
Drug · Other · Device
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
10
States / cities
Fremont, California • Aventura, Florida • Rolling Meadows, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 22, 2026, 5:12 AM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream in Participants With Mild or Moderate Atopic Dermatitis

NCT03903822
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PF-06700841, Vehicle (Placebo)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 75 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
36
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Encinitas, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Oct 22, 2026, 5:12 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Assessment of the Effect of Coconut and Sunflower Seed Oil Derived Isosorbide Diseters and Colloidial Oatmeal

NCT05688735
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Isosorbide Diester Moisturizer, Control Moisturizer
Other
Lead sponsor
Integrative Skin Science and Research
Industry
Eligibility
2 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2023 · Synced Oct 22, 2026, 5:12 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA

NCT06393452
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
PP405 0.05% Topical Gel, Topical Vehicle Gel
Drug
Lead sponsor
Pelage Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
8
States / cities
Encinitas, California • Thousand Oaks, California • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 22, 2026, 5:12 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of the Safety and Anesthetic Effect of AG-920 Topical Ophthalmic Solution

NCT04513652
View directory record Official record
Conditions
Anesthesia, Local
Interventions
AG-920, Placebo
Drug
Lead sponsor
American Genomics, LLC
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 22, 2026, 5:12 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Double-blind Placebo-controlled Trial of Generic Clindamycin/Benzoyl Peroxide Gel Versus Onexton Gel in Acne Vulgaris

NCT02616614
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Onexton, Clindamycin/benzoyl peroxide gel, Placebo
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
862 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
17
States / cities
Phoenix, Arizona • Chula Vista, California • La Mesa, California + 14 more
Source: ClinicalTrials.gov public record
Updated May 27, 2020 · Synced Oct 22, 2026, 5:12 AM EDT
Terminated Phase 2 Interventional

Single Dose Enteral Tranexamic Acid in Critically Ill Patients

NCT01683747
View directory record Official record
Conditions
Shock, Sepsis, Hypotension, Critical Illness
Interventions
Tranexamic Acid, Control Intervention (Carrier fluid only)
Drug
Lead sponsor
San Diego Veterans Healthcare System
Federal
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Oct 22, 2026, 5:12 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of IDP 118 in the Treatment of Plaque Psoriasis

NCT02045277
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
IDP-118 Lotion, IDP-118 Monad HP Lotion, IDP-118 Monad Taz Lotion, IDP-118 Vehicle Lotion
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
18
States / cities
Encino, California • San Diego, California • Santa Rosa, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2020 · Synced Oct 22, 2026, 5:12 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy

NCT05617820
View directory record Official record
Conditions
Dyspareunia
Interventions
Estradiol, Imvexxy, Placebo
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
40 Years to 75 Years · Female only
Enrollment
1,050 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
42
States / cities
Birmingham, Alabama • Chandler, Arizona • Sacramento, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 22, 2026, 5:12 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Effect of ATX-101 on QT/QTc Intervals

NCT01706679
View directory record Official record
Conditions
Healthy
Interventions
ATX-101 (10 mg/ml), ATX-101 (20 mg/ml), Moxifloxacin (400 mg), Placebo vehicle (PBS)
Drug
Lead sponsor
Kythera Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
218 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Nov 14, 2013 · Synced Oct 22, 2026, 5:12 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome

NCT06050122
View directory record Official record
Conditions
Gorlin Syndrome
Interventions
Patidegib Topical Gel, Patidegib Topical Gel with no active patidegib
Drug
Lead sponsor
Sol-Gel Technologies, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
24
States / cities
Rogers, Arkansas • Fremont, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 22, 2026, 5:12 AM EDT
Completed Phase 3 Interventional Results available

Bioequivalence Study of Clindamycin Gel 1% in Treatment of Acne Vulgaris

NCT03522441
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Clindamycin 1% Gel, Placebo
Drug
Lead sponsor
Akorn, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
1,125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
10
States / cities
Encino, California • Sherman Oaks, California • Brandon, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Oct 22, 2026, 5:12 AM EDT
Completed Not applicable Interventional Results available

HylaCare in the Treatment of Acute Skin Changes in Patients Undergoing Radiotherapy for Breast Cancer

NCT02165605
View directory record Official record
Conditions
Breast Cancer
Interventions
HylaCare, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 22, 2026, 5:12 AM EDT
Completed Phase 3 Interventional Results available

Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)

NCT04052425
View directory record Official record
Conditions
Non-segmental Vitiligo
Interventions
Ruxolitinib cream, Vehicle
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
29
States / cities
Hoover, Alabama • Scottsdale, Arizona • Hot Springs, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 22, 2026, 5:12 AM EDT
Completed Phase 2 Interventional

Dose Response Study of Patients With Erythematous Rosacea

NCT01186068
View directory record Official record
Conditions
Erythematous (Type One) Rosacea
Interventions
V-101, vehicle
Drug · Other
Lead sponsor
Vicept Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
7
States / cities
San Diego, California • Miami Beach, Florida • Louisville, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2010 · Synced Oct 22, 2026, 5:12 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Phototoxicity Potential of 6% Bemotrizinol

NCT05254925
View directory record Official record
Conditions
Phototoxic Response
Interventions
Sunscreen oil with 6% Bemotrizinol, Sunscreen oil vehicle, Dispersion of 6% BEMT in petrolatum, Petrolatum vehicle
Drug · Other
Lead sponsor
dsm-firmenich Switzerland AG
Industry
Eligibility
18 Years to 75 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 26, 2022 · Synced Oct 22, 2026, 5:12 AM EDT
Suspended Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Tanfanercept (HL036) in Dry Eye Disease

NCT06400589
View directory record Official record
Conditions
Dry Eye
Interventions
tanfanercept, Vehicle
Drug
Lead sponsor
HanAll BioPharma Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Delray Beach, Florida
Source: ClinicalTrials.gov public record
Updated May 31, 2024 · Synced Oct 22, 2026, 5:12 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Steroid-reducing Effects of Crisaborole

NCT03832010
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Crisaborole, Hydrocortisone Ointment, Triamcinolone ointment, Aquaphor
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
2 Years to 17 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 19, 2024 · Synced Oct 22, 2026, 5:12 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of BTX 1503 in Patients With Moderate to Severe Acne Vulgaris

NCT03573518
View directory record Official record
Conditions
Acne Vulgaris
Interventions
BTX 1503, Vehicle
Drug
Lead sponsor
Botanix Pharmaceuticals
Industry
Eligibility
12 Years to 40 Years
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
25
States / cities
Little Rock, Arkansas • Encino, California • Murrieta, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2022 · Synced Oct 22, 2026, 5:12 AM EDT